Skip to main content
OpenTrials
Completed

NCT Number: NCT02541396

A Study Of The Effectiveness Of Wafermine Alone And In Combination With Opioids In Subjects Undergoing Bunionectomy

To evaluate the safety and effectiveness of Wafermine administered with and without an opioid medication for acute pain following bunionectomy surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Jean Brown Research

Salt Lake City, Utah, 84124, United States

About this study

This is a Phase 2, randomised, double-blind, double-dummy, placebo-controlled evaluation of the analgesic efficacy and safety of WafermineTM alone and in combination with low-dose oxycodone in adult subjects who experience post-operative pain after undergoing primary unilateral bunionectomy. The study will randomise sufficient subjects to have 72 completed subjects at 1 site.

Study subjects will receive multiple doses of study medication over a 14 hour period and will be asked to complete pain and relief assessments as well as tolerability questionnaires over a 24 hour period.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Scheduled for a bunionectomy (with no additional procedures).
  • Healthy, ambulatory subjects able to understand and willing to comply with study procedures, study restrictions and requirements.
  • Body mass index (BMI) ≥19 to ≤33 kg/m2.
  • Females: Not pregnant, not lactating, and not planning to become pregnant during the study.
  • Females: Be abstinent, surgically sterile, at least two years post-menopausal; or medically acceptable contraception.
  • Able to read and understand English.
  • Able to swallow oral capsules whole.

Exclusion criteria

  • Allergy, intolerance, or contraindication to ketamine, oxycodone, morphine, ibuprofen or surgical medications.
  • Clinically significant medical condition.
  • History of illicit drug use or alcohol abuse and not in full remission.
  • Positive test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) at the screening visit.
  • Clinically significant 12 lead ECG abnormalities at screening.
  • Smokers who are unwilling to abstain during the inpatient stay.

Treatment and study plan

Wafermine

Drug

35 or 70 mg ketamine in a sublingual wafer

Other names: Sublingual ketamine

Oxycodone

Drug

5 mg oxycodone capsule

Placebo

Drug

Placebo capsule or placebo wafer

Primary outcomes

  1. Total Pain Relief (TOTPAR)

    Time frame: 24 hours

    Subjects will use an 11 point numerical pain rating scale (NPRS) where 0=No Pain and 10= Worst Possible pain to rate their pain at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16 and 24 hours.

    TOTPAR is computed as follows at the specified time points: TOTPAR-t = ∑ [T(i) - T(i-1) * [(PR(i-1) + PR(i))/2]

Secondary outcomes

  1. Percent with maximum Pain Relief

    Time frame: 24 hours

    The percent of maximum pain relief is defined as the proportion of subjects reporting "Complete Relief" (score of 4) on a 4 point categorical scale (no relief, a little relief, some relief, a lot of relief and complete relief) at each time point over the sampling interval.

  2. Proportion of Subjects requiring "Rescue Medication"

    Time frame: 24 hours

    Calculation of the proportion of subjects requiring "Rescue Medication" at each time point over the sampling interval.

  3. Time to onset of perceptible and meaningful pain relief

    Time frame: 24 hours

    Calculated using the double stopwatch technique. Subjects stop the first stopwatch when they experience perceptible relief and the second stopwatch when they experience meaningful relief.

  4. Time to onset of complete pain relief (Peak Relief)

    Time frame: 24 hours

    Measurement of the time it takes subjects to report their maximum pain relief on a 5 point categorical relief scale (0=no relief, 1=a little relief, 2=some relief, 3=a lot of relief, 4=complete relief)

  5. Time to maximum reduction in pain intensity

    Time frame: 24 hours

    Measurement of the time it takes subjects to reach their maximum reduction in pain on the 11 point NPRS where 0=No pain and 10=Worst Possible pain.

  6. Time for pain intensity to return to baseline

    Time frame: 24 hours

    Measurement of the time for pain intensity to return to baseline using scores from the NPRS assessments where 0=No pain and 10=Worst possible pain.

  7. Time to rescue medication

    Time frame: 24 hours

    Measurement of the time elapsed from initial dose of study medication to time of first dose of rescue medication.

  8. Percentage of Maximum Total Pain Relief (TOTPAR)

    Time frame: 24 hours

    Subjects will use an 11 point numerical pain rating scale (NPRS) where 0=No Pain and 10= Worst Possible pain to rate their pain at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16 and 24 hours. Percentage of Maximum Total Pain Relief is computed at each time-point using:

    %maxTOTPAR= 〖TOTPAR〗_t/〖maxTOTPAR〗_t x100

  9. Sum of Pain Intensity Differences (SPID)

    Time frame: 24 hours

    Subjects will use an 11 point numerical pain rating scale (NPRS) where 0-No Pain and 10= Worst Possible pain to rate their pain at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16 and 24 hours.

    Sum of Pain Intensity Differences is computed at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16 and 24 hours. SPIDx is a time weighted sum of pain intensity difference score from baseline over the time interval in hours.

  10. Responder Rates (30% and 50%)

    Time frame: 24 hours

    The responder rate is defined as the proportion of subjects with a value of percentage change greater than or equal to 30% (and 50%) from baseline in pain intensity (using scores from the 11 point NPRS where 0=no pain and 10=worst possible pain) at each time point over the sampling interval.

  11. Safety (treatment emergent adverse events, significant changes in physical examination findings as well as vital sign measurements)

    Time frame: 24 hours

    Measurement of treatment emergent adverse events reported during the study. Measurement of significant changes in physical examination findings as well as vital sign measurements (heart rate, blood pressure, breathing rate and pulse oximetry readings).

  12. Tolerability (judged by subject answers on oral symptoms questionnaire)

    Time frame: 24 hours

    Measurement of tolerability as judged by subject answers on oral symptoms questionnaire measuring irritation, burning and bitterness, as well as physical examination of oral cavity. Also measuring the number of subjects who discontinue the study due to intolerable side effects.

Sponsors and collaborators

Lead sponsor

iX Biopharma Ltd.

Other

Collaborators

  • Jean Brown Research

Registry information

Official study title

A Pilot Study Of The Efficacy Of WafermineTM Alone And In Combination With Opioids In Subjects Undergoing Bunionectomy

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Sep 4, 2015
Registry last updated
Feb 23, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.